{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T06:26:37Z","timestamp":1770531997877,"version":"3.49.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Institute for Medical Research and Occupational Health"},{"name":"University North"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.cbi.2018.08.009","type":"journal-article","created":{"date-parts":[[2018,8,18]],"date-time":"2018-08-18T11:57:40Z","timestamp":1534593460000},"page":"128-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Effects of \u03949-tetrahydrocannabinol on irinotecan-induced clinical effects in rats"],"prefix":"10.1016","volume":"294","author":[{"given":"Ljerka","family":"Prester","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Mikoli\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreja","family":"Juri\u010d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nino","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1850-3808","authenticated-orcid":false,"given":"Marijana","family":"Neuberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Luci\u0107 Vrdoljak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irena","family":"Br\u010di\u0107 Kara\u010donji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2018.08.009_bib1","first-page":"137","article-title":"Established and potential therapeutic applications of cannabinoids in oncology","volume":"11","author":"Walsh","year":"2003","journal-title":"Support. Care Canc."},{"key":"10.1016\/j.cbi.2018.08.009_bib2","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.2147\/OTT.S106944","article-title":"Endocannabinoid system as a regulator of tumor cell malignancy \u2013 biological pathways and clinical significance","volume":"9","author":"Pyszniak","year":"2016","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.cbi.2018.08.009_bib3","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1634\/theoncologist.11-7-742","article-title":"Herb-drug interactions in oncology: focus on mechanisms of induction","volume":"11","author":"Meijerman","year":"2006","journal-title":"Oncol."},{"key":"10.1016\/j.cbi.2018.08.009_bib4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1089\/can.2015.0012","article-title":"Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy","volume":"1","author":"Ujv\u00e1ry","year":"2016","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.cbi.2018.08.009_bib5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/sj.bjc.6600447","article-title":"Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38","volume":"87","author":"Mathijssen","year":"2002","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.cbi.2018.08.009_bib6","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.forsciint.2012.08.013","article-title":"Distribution of free and conjugated cannabinoids in human bile samples","volume":"223","author":"Fabritius","year":"2012","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.cbi.2018.08.009_bib7","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/cbdv.200790152","article-title":"Human cannabinoid pharmacokinetics","volume":"4","author":"Huestis","year":"2007","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.cbi.2018.08.009_bib8","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.3892\/ol.2017.6016","article-title":"Ocoxin oral solution\u00ae as a complement to irinotecan chemotherapy in the metastatic progression of colorectal cancer to the liver","volume":"13","author":"Hernandez-Unzueta","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.cbi.2018.08.009_bib9","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ctrv.2008.05.002","article-title":"Clinical and pharmacogenetic factors associated with irinotecan toxicity","volume":"34","author":"Kweekel","year":"2008","journal-title":"Canc. Treat Rev."},{"key":"10.1016\/j.cbi.2018.08.009_bib10","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2174\/1389450111314070007","article-title":"Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis","volume":"14","author":"Swami","year":"2013","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.cbi.2018.08.009_bib11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s002800000151","article-title":"Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats","volume":"46","author":"Kurita","year":"2000","journal-title":"Canc. Chemother. Pharmacol."},{"key":"10.1016\/j.cbi.2018.08.009_bib12","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.4161\/cbt.6.9.4567","article-title":"Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity","volume":"6","author":"de Jong","year":"2007","journal-title":"Canc. Biol. Ther."},{"key":"10.1016\/j.cbi.2018.08.009_bib13","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.3748\/wjg.v22.i16.4250","article-title":"Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy","volume":"22","author":"Yu","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cbi.2018.08.009_bib14","first-page":"1085","article-title":"Circulating inflammatory mediators during start of fever in differential diagnosis of gram-negative and gram-positive infections in leukopenic rats","volume":"12","author":"Tavares","year":"2005","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"10.1016\/j.cbi.2018.08.009_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF02962366","article-title":"An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic cancer patients","volume":"26","author":"Engel","year":"1998","journal-title":"Infection"},{"key":"10.1016\/j.cbi.2018.08.009_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4081\/hr.2014.5466","article-title":"Intensive serial biomarker profiling for the prediction of neutropenic fever in patients with hematologic malignancies undergoing chemotherapy: a pilot study","volume":"6","author":"Chan","year":"2014","journal-title":"Hematol. Rep."},{"key":"10.1016\/j.cbi.2018.08.009_bib17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.canlet.2009.04.005","article-title":"Cannabinoids in the treatment of cancer","volume":"285","author":"Alexander","year":"2009","journal-title":"Canc. Lett."},{"key":"10.1016\/j.cbi.2018.08.009_bib18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2174\/157488410793352049","article-title":"Cannabis-derived substances in cancer therapy \u2013 an emerging anti-inflammatory role for the cannabinoids","volume":"5","author":"Liu","year":"2010","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2018.08.009_bib19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/sj.bjp.0707486","article-title":"Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation","volume":"153","author":"Wright","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cbi.2018.08.009_bib20","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1098\/rstb.2011.0381","article-title":"Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities","volume":"367","author":"Pertwee","year":"2012","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"10.1016\/j.cbi.2018.08.009_bib21","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/cpt.115","article-title":"Medicinal chemistry of cannabinoids","volume":"97","author":"Vemuri","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cbi.2018.08.009_bib22","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.3747\/co.23.3080","article-title":"Anticancer mechanisms of cannabinoids","volume":"23","author":"Velasco","year":"2016","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.cbi.2018.08.009_bib23","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.3747\/co.23.3099","article-title":"Integrating cannabis into clinical cancer care","volume":"23","author":"Abrams","year":"2016","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.cbi.2018.08.009_bib24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/bmc.1130030109","article-title":"Determination of \u03941\u2010tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography\u2013mass spectrometry","volume":"3","author":"Johansson","year":"1989","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.cbi.2018.08.009_bib25","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1200\/JCO.2002.08.177","article-title":"Modulation of irinotecan metabolism by ketoconazole","volume":"20","author":"Kehrer","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cbi.2018.08.009_bib26","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s10147-012-0425-5","article-title":"Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer","volume":"18","author":"Sasaki","year":"2013","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.cbi.2018.08.009_bib27","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/bcp.12563","article-title":"Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment","volume":"79","author":"Waters","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2018.08.009_bib28","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1517\/17425255.2010.510132","article-title":"Effects of herbal products on the metabolism and transport of anticancer agents","volume":"6","author":"He","year":"2010","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.cbi.2018.08.009_bib29","first-page":"3717","article-title":"Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose","volume":"60","author":"Cao","year":"2000","journal-title":"Canc. Res."},{"key":"10.1016\/j.cbi.2018.08.009_bib30","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1046\/j.1440-1746.2003.03136.x","article-title":"Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer","volume":"18","author":"Gibson","year":"2003","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cbi.2018.08.009_bib31","doi-asserted-by":"crossref","first-page":"6461","DOI":"10.4049\/jimmunol.164.12.6461","article-title":"\u03949-Tetrahydrocannabinol treatment suppresses immunity and early IFN-, IL-12, and IL-12 receptor 2 responses to Legionella pneumophila infection","volume":"164","author":"Klein","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.cbi.2018.08.009_bib32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1006\/faat.1996.0048","article-title":"Toxicity and carcinogenicity of \u03949-tetrahydrocannabinol in Fischer rats and B6C3F1 mice","volume":"30","author":"Chan","year":"1996","journal-title":"Fund. Appl. Toxicol."},{"key":"10.1016\/j.cbi.2018.08.009_bib33","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/ijc.21082","article-title":"Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats","volume":"116","author":"Gibson","year":"2005","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.cbi.2018.08.009_bib34","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1634\/theoncologist.12-3-291","article-title":"Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel","volume":"12","author":"Engels","year":"2007","journal-title":"Oncol."},{"key":"10.1016\/j.cbi.2018.08.009_bib35","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/jnci\/djm115","article-title":"UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters","volume":"99","author":"Hoskins","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.cbi.2018.08.009_bib36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/sj.bjc.6603831","article-title":"Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma","volume":"97","author":"Yamanaka","year":"2007","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.cbi.2018.08.009_bib37","first-page":"92","article-title":"Prognostic value of chemotherapy-induced leukopenia in small-cell lung cancer","volume":"10","author":"Liu","year":"2013","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.cbi.2018.08.009_bib38","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(05)70255-2","article-title":"Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials","volume":"6","author":"Di Maio","year":"2005","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cbi.2018.08.009_bib39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.plipres.2011.01.001","article-title":"Is lipid signaling through cannabinoid 2 receptors part of a protective system?","volume":"50","author":"Pacher","year":"2011","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.cbi.2018.08.009_bib40","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1007\/s11095-005-4585-0","article-title":"St. John's wort modulates the toxicities and pharmacokinetics of CPT-11 (Irinotecan) in rats","volume":"22","author":"Hu","year":"2005","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.cbi.2018.08.009_bib41","first-page":"154","article-title":"Evaluation of \u03949-tetrahydrocannabinol metabolites and oxidative stress in type 2 diabetic rats, Iran","volume":"19","author":"Coskun","year":"2016","journal-title":"J. Basic Med. Sci."},{"key":"10.1016\/j.cbi.2018.08.009_bib42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/cells5020015","article-title":"Roles of NF-\u03baB in cancer and inflammatory diseases and their therapeutic approaches","volume":"5","author":"Park","year":"2016","journal-title":"Cells"},{"key":"10.1016\/j.cbi.2018.08.009_bib43","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00280-007-0534-4","article-title":"Role of cytokines (TNF-\u03b1, IL-1\u03b2 and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide","volume":"61","author":"Melo","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.cbi.2018.08.009_bib44","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","article-title":"Pharmacokinetics and pharmacodynamics of cannabinoids","volume":"42","author":"Grotenhermen","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.cbi.2018.08.009_bib45","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.bcp.2010.01.028","article-title":"Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes","volume":"79","author":"Yamaori","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2018.08.009_bib46","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/1535-7163.MCT-10-0688","article-title":"A combined preclinical therapy of cannabinoids and temozolomide against glioma","volume":"10","author":"Torres","year":"2011","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.cbi.2018.08.009_bib47","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3390\/molecules23061332","article-title":"Irinotecan and \u03949-tetrahydrocannabinol interactions in rat liver: a preliminary evaluation using biochemical and genotoxicity markers","volume":"23","author":"Luci\u0107 Vrdoljak","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.cbi.2018.08.009_bib48","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.clinthera.2011.01.022","article-title":"Consensus-based evaluation of clinical significance and management of anticancer drug interactions","volume":"33","author":"Jansman","year":"2011","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.cbi.2018.08.009_bib49","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13311-015-0380-8","article-title":"Safety and toxicology of cannabinoids","volume":"12","author":"Sachs","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.cbi.2018.08.009_bib50","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.2174\/092986710791111279","article-title":"Herbal interactions with anticancer drugs: mechanistic and clinical considerations","volume":"17","author":"Yang","year":"2010","journal-title":"Curr. Med. Chem."},{"issue":"Suppl. 2","key":"10.1016\/j.cbi.2018.08.009_bib51","first-page":"S81","article-title":"Interactions of natural health products with biomedical cancer treatments","volume":"15","author":"Seely","year":"2008","journal-title":"Curr. Oncol."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279718308792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279718308792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T13:51:29Z","timestamp":1757857889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279718308792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":51,"alternative-id":["S0009279718308792"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2018.08.009","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of \u03949-tetrahydrocannabinol on irinotecan-induced clinical effects in rats","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2018.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}